Media statements

Roche submits science-based targets for net zero by 2045Roche enters into a definitive agreement with Lonza, which will acquire the Genentech manufacturing facility in Vacaville, California, USARoche actively advances sector decarbonisation ahead of COP28Roche launches a new addition to the cobas® connection modules, the CCM Vertical, helping to improve laboratory efficiencyFDA grants accelerated approval of Elevidys™, the first gene therapy to treatRoche to divest legacy Genentech facility in Vacaville, California, as part of long-term strategy to evolve manufacturing capabilitiesAdoption of the Resolution on Strengthening Diagnostics capacity at the 76th World Health AssemblyCHMP recommends Ronapreve for the treatment of hospitalised COVID-19 patientsRoche statement on FDA Oncologic Drug Advisory meeting on 9 March 2023Roche provides update on Tecentriq US indication for previously untreated metastatic bladder cancerRoche signs up to the Science Based Targets initiative and the Sustainable Markets Initiative to further deepen the commitment to climate actionsRoche and the World Health Organization partner to improve access to Actemra®/RoActemra® (tocilizumab) for COVID-19 in low- and middle-income countriesAdditional studies confirm Roche SARS-CoV-2 Rapid Antigen Tests’ sensitivity against Omicron variantViruses mutate over time, and SARS-CoV-2 is no exceptionHow Roche tests and medicines continue to play a key role as pandemic evolvesRonapreve does not retain neutralising activity against the Omicron variantRoche statement on termination of partnership with Atea Pharmaceuticals to develop AT-527Roche statement on follow-up analysis of Ronapreve phase III prevention trialWHO recommends the use of Ronapreve™ (casirivimab and imdevimab) in COVID-19 patientsRoche statement on global supply constraints of Actemra/RoActemraWorld Health Organization issues new treatment recommendations for the clinical management of COVID-19Roche statement on the preliminary phase III data from UK University of Oxford-led RECOVERY trial for casirivimab and imdevimabRoche statement on FDA Oncologic Drug Advisory Meetings on 27–29 April 2021Roche statement on the European Medicines Agency (EMA) commencement of review for Regeneron’s antibody cocktail (casirivimab and imdevimab)Roche statement on casirivimab and imdevimab data in preventing COVID-19 infections within householdsRoche statement on casirivimab and imdevimab data in hospitalised patientsRoche statement on new variants of SARS-CoV-2 found in the UKRoche statement on FDA acceptance of casirivimab and imdevimab (REGNCOV2) EUA in the USChanges recommended to ongoing REGN-COV2 study in hospitalized patients by Independent Data Monitoring CommitteeRoche statement on REGN-COV2 data in non-hospitalised patientsRoche statement on REGN-COV2 US Emergency Use Authorization RequestRoche statement regarding UK diagnostics products supply issueRoche statement on REGN-COV2 virology phase II data

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeCovid-19Pharma solutionsRoche careersMedia libraryAnnual Report 2023Privacy policyLegal statementAccessibility statement